ImpediMed Ltd
ASX:IPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ImpediMed Ltd
ASX:IPD
|
AU |
|
I
|
Industrial and Commercial Bank of China Ltd
F:ICK
|
CN |
|
E-Power Resources Inc
F:8RO
|
CA |
|
DENTSPLY SIRONA Inc
F:DY2
|
US |
|
C
|
Cloudflare Inc
DUS:8CF
|
US |
|
S
|
Sung Kwang Bend Co Ltd
KOSDAQ:014620
|
KR |
|
Colonial Coal International Corp
F:COX
|
CA |
|
JMDC Inc
F:6JM
|
JP |
|
T
|
The Nature Holdings Co Ltd
KOSDAQ:298540
|
KR |
|
UBM Development AG
F:2U2
|
AT |
|
K
|
Kingspan Group PLC
XMUN:KRX
|
IE |
|
M
|
METRO AG
XHAM:B4B0
|
DE |
|
M
|
Marathon Petroleum Corp
F:MPN
|
US |
|
G
|
General Copper Gold Corp
F:7S50
|
CA |
|
Noble Corporation PLC
F:85V1
|
US |
|
5
|
5E Advanced Materials Inc
NASDAQ:FEAM
|
US |
Earnings Calls
Last Earnings Call
Execution: Management said sales improved quarter on quarter, with 40 units sold, but still fell short of plan and the team is not satisfied with the pace of conversion.
Reimbursement: National coverage rose to 95%, or 331 million covered lives, which management said should help both new customer wins and reengagement with existing accounts.
Funding: The company raised $15.3 million in the quarter and used $5 million to partially repay debt, leaving a cash balance of $15.3 million.
Cost control: Leadership highlighted a $5 million annualized operating cost reduction and said savings should flow through at about $1 million to $1.5 million per quarter.
Growth areas: The company is pushing growth in cancer survivorship, heart failure monitoring, and body composition/weight management, with management emphasizing disciplined commercial execution over hype.